KCA
Search
- Page Path
- HOME > Search
Case Report
- Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
- Won-Young Park, Han-Jo Kim, Kyoungha Kim, Sang-Byung Bae, Namsu Lee, Kyu-Taek Lee, Jong-Ho Won, Hee-Sook Park, Sang-Cheol Lee
- Cancer Res Treat. 2016;48(2):843-847. Published online March 2, 2015
- DOI: https://doi.org/10.4143/crt.2014.234
-
Abstract
PDF
PubReader
ePub - Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis.
-
Citations
Citations to this article as recorded by
- An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
Mainak Bardhan, Debankur Dey, Vinay Suresh, Binish Javed, Vyshak Alva Venur, Neha Joe, Ritvika Kalidindi, Ahmad Ozair, Marium Khan, Reshma Mahtani, Simon Lo, Yazmin Odia, Manmeet S. Ahluwalia
Expert Review of Neurotherapeutics.2024; 24(1): 77. CrossRef - Intrathecal Trastuzumab for HER2-Positive Cancer of Unknown Primary Leptomeningeal Metastasis: A Case Report
Kohei Oka, Shun Futamura, Taishi Harada
Cureus.2024;[Epub] CrossRef - A Review on the Efficacy and Safety of Intrathecal Administration of
Novel Medications for Leptomeningeal Metastases in Solid Cancers
Fatemeh Jafari, Mohammad Moeini Nodeh, Hesamoddin Hosseinjani, Hamed Baharara, Sajad Azad, Omid Arasteh, Thomas P. Johnston, Amirhossein Sahebkar
Current Medicinal Chemistry.2024; 31(19): 2732. CrossRef - Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers
Rachna Malani, Ankush Bhatia, Allison Betof Warner, Jonathan T. Yang
Seminars in Neurology.2023; 43(06): 859. CrossRef - Leptomeningeal metastases: the future is now
Rimas V. Lukas, Jigisha P. Thakkar, Massimo Cristofanilli, Sunandana Chandra, Jeffrey A. Sosman, Jyoti D. Patel, Priya Kumthekar, Roger Stupp, Maciej S. Lesniak
Journal of Neuro-Oncology.2022; 156(3): 443. CrossRef - Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
Yajing Chi, Mao Shang, Liang Xu, Heyi Gong, Rongjie Tao, Lihua Song, Baoxuan Zhang, Sha Yin, Binbin Cong, Huihui Li
Frontiers in Oncology.2022;[Epub] CrossRef - Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression
Flora Zagouri, Panagiotis Zoumpourlis, Emilie Le Rhun, Rupert Bartsch, Eleni Zografos, Kleoniki Apostolidou, Meletios-Athanasios Dimopoulos, Matthias Preusser
Cancer Treatment Reviews.2020; 88: 102046. CrossRef - Leptomeningeal carcinomatosis in patients with breast cancer
Maria Alice Franzoi, Gabriel N. Hortobagyi
Critical Reviews in Oncology/Hematology.2019; 135: 85. CrossRef - Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy
Nicholas B. Figura, Victoria T. Rizk, Homan Mohammadi, Brittany Evernden, Sepideh Mokhtari, H. Michael Yu, Timothy J. Robinson, Arnold B. Etame, Nam D. Tran, James Liu, Iman Washington, Roberto Diaz, Brian J. Czerniecki, Hatem Soliman, Hyo S. Han, Solmaz
Breast Cancer Research and Treatment.2019; 175(3): 781. CrossRef - Breast leptomeningeal disease: a review of current practices and updates on management
Nicholas B. Figura, Victoria T. Rizk, Avan J. Armaghani, John A. Arrington, Arnold B. Etame, Hyo S. Han, Brian J. Czerniecki, Peter A. Forsyth, Kamran A. Ahmed
Breast Cancer Research and Treatment.2019; 177(2): 277. CrossRef - Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
Kelsey M Bowman, Priya Kumthekar
Future Oncology.2018; 14(4): 391. CrossRef - Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience
Nicholas B. Figura, Wendy Long, Michael Yu, Timothy J. Robinson, Sepideh Mokhtari, Arnold B. Etame, Nam D. Tran, Roberto Diaz, Hatem Soliman, Heather S. Han, Solmaz Sahebjam, Peter A. Forsyth, Kamran A. Ahmed
Breast Cancer Research and Treatment.2018; 169(2): 391. CrossRef - Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
Niyanta N. Kumar, Michelle E. Pizzo, Geetika Nehra, Brynna Wilken-Resman, Sam Boroumand, Robert G. Thorne
Bioconjugate Chemistry.2018; 29(12): 3937. CrossRef - Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
J. Remon, E. Le Rhun, B. Besse
Cancer Treatment Reviews.2017; 53: 128. CrossRef - Current challenges in the management of breast cancer brain metastases
Ciara C. O’Sullivan, Nicole N. Davarpanah, Jame Abraham, Susan E. Bates
Seminars in Oncology.2017; 44(2): 85. CrossRef - Leptomeningeal disease: current diagnostic and therapeutic strategies
Gautam Nayar, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly L. Blackwell, Jeffrey M. Clarke, Shivanand P. Lad, Peter E. Fecci
Oncotarget.2017; 8(42): 73312. CrossRef - Leptomeningeal metastases of solid cancer
Emilie Le Rhun, Evanthia Galanis
Current Opinion in Neurology.2016; 29(6): 797. CrossRef - Metastatic breast cancer: The Odyssey of personalization
A. Sonnenblick, N. Pondé, M. Piccart
Molecular Oncology.2016; 10(8): 1147. CrossRef - Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
Eleonora Teplinsky, Francisco J. Esteva
Current Oncology Reports.2015;[Epub] CrossRef
- An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
- 16,157 View
- 190 Download
- 20 Web of Science
- 19 Crossref
Original Articles
- Leptomeningeal Carcinomatosis in Solid Tumors; Clinical Manifestation and Treatment
- Joon Oh Park, Hyun Joon Shin, Hyung Jong Kim, Sang Wook Lee, Hei Cheul Jeung, Seung Min Kim, Nae Choon Yoo, Hyun Cheol Chung, Joo Hang Kim, Byung Soo Kim, Jin Sik Min, Jae Kyung Roh
- J Korean Cancer Assoc. 2001;33(1):34-40.
-
Abstract
PDF
- PURPOSE
Leptomeningeal carcinomatosis occurs in about 5% of patients with solid tumor and is being diagnosed with increasing frequency as patients live longer and as neuro-imaging studies improve. In general, the most commom cancers that involved the leptomeninges are breast cancer, lung cancer, and malignant melanoma.
MATERIALS AND METHODS
We investigated 25 patients presented with multiple neurologic symptoms and signs who were diagnosed with leptomeningeal carcinomatosis at the Yonsei Cancer Center from January 1990 to December 1999.
RESULTS
The primary disease of leptomeningeal carcinomatosis were stomach cancer (10 cases), breast cancer (7 cases), lung cancer (5 cases), unknown primary cancer (2 cases) and common bile duct cancer (1 case). All patients were presented with multiple neurologic symptoms and signs involving the central nervous system (CNS), cranial nerve or spinal nerves. Twenty-one of twenty- five patients were treated with intrathecal chemotherapy, radiotherapy, or combination therapy. Fourteen of them (66.7%) experienced improvement or stabilization of neurologic symptom and sign. The median survival was 122 days (10-2190).
CONCLUSION
In conclusion, although early diagnosis and active treatment of leptomeningeal carcinomatosis may improve the quality of life in selected patients, the median survival was relatively short. Therefore, new diagnostic and therapeutic strategy for leptomeningeal carcinomatosis were needed.
- 2,843 View
- 18 Download
- Brain Metastasis and Leptomeningeal Carcinomatosis in Breast Cancer
- Yoon Soo Chang, Jeong Hun Seo, Ruth Lee, Joong Bae Ahn, Kwang Yong Shim, Soo Jung Gong, Hwa Young Lee, Sun Young Rha, Nae Choon Yoo, Chang Ok Suh, Joo Hang Kim, Jae Kyung Rho, Kyong Sik Lee, Jin Sik Min, Byung Soo Kim, Hyun Cheol Chung
- J Korean Cancer Assoc. 1998;30(3):464-474.
-
Abstract
PDF
- PURPOSE
Brain metastasis is estimated to occur in 20 to 40% of cancer patients, and meningeal involvement has been reported in 5% to 8% of cancer patients. Even if the prognosis is grave, standard treatment modality of brain metastasis or leptomeningeal carcinomatosis has not been established. We evaluated the prognosis and the clinical features of the brain and leptomeningeal metastasis of the breast cancer.
MATERIALS AND METHODS
The 43 patients who was diagnosed as brain parenchymal metastasis or leptomeningeal carcinomatosis clinically, radiologically and/or cytologically were included in this study. The median age was 44(range: 27-61) years.
RESULTS
The median duration from brain metastasis to death was 181 days(range: 8~1599), and the median duration from leptomeningeal carcinomatosis to death was 39 days(range: 25~152). Age(p=0.7174) and number of brain metastatic lesion(p=0.4097) did not influence the survival, but the presence of other systemic metastatic lesion affected the survival(p 0.0224). When we compared the survival rates of patients according to treatment modality, the patients with systemic chemotherapy versus patients without systemic chemotherapy showed differences(p= 0.0009). Patients treated with whole brain radiation only versus patients with whole brain radiation and other systemic management also showed different survival rate(p=0.0009). But intrathecal chemotherapy had no effect on survival. Well differentiated, solitary lesions were treated by operation and/or gamma-knife surgery, and their effects were good.
CONCLUSION
Prolongation of survival was suggested with whole brain radiotherapy combined with systemic treatment in brain or leptomeningeal metastasis. Further study is expected to confirm this finding.
- 3,494 View
- 32 Download
First
Prev
